Cipla Ltd

Cipla Invests in iCaltech to Boost Respiratory Diagnostics 🏥💡

- Cipla acquires 20% voting rights in iCaltech for ~INR 5 crore.

- iCaltech is a Bangalore-based medical devices firm specializing in respiratory diagnostics.

- iCaltech’s revenue: INR 6.70 cr (FY25), up from INR 4.19 cr (FY24) and INR 1.28 cr (FY23).

- Cipla ranks 3rd in Indian pharma and 4th in US generic inhalation products.

- iCaltech is ISO 13485 certified, focusing on regulatory-approved diagnostic devices.

- Partnership aligns with Cipla’s focus on digital, devices, and diagnostics in healthcare.

- Deal expected to close within 1 month.